Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Velcheti · SciRah

Researcher profile · Semantic Scholar

V. Velcheti

Share profile

V. Velcheti — researcher profile on SciRah

h-index: 66
Works: 373
Citations: 19K

Most-cited papers

Sotorasib for Lung Cancers with KRAS p.G12C Mutation
F. Skoulidis, Bob T. Li, G. Dy, T. Price +22 more
2021New England Journal of Medicine1,394 citations Open access
Semantic Scholar
The current state of the art and future trends in RAS-targeted cancer therapies
S. Punekar, V. Velcheti, B. Neel, Kwok-Kin Wong
2022Nature Reviews Clinical Oncology454 citations Open access
Semantic Scholar
Repotrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
A. Drilon, D. Camidge, J. Lin, Sang-we Kim +29 more
2024New England Journal of Medicine187 citations Open access
Semantic Scholar
Squamous cell lung cancer: Current landscape and future therapeutic options.
S. Lau, Yuanwang Pan, V. Velcheti, Kwok Kei Sandra Wong
2022Cancer Cell185 citations Open access
Semantic Scholar
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Arvind Ravi, M. Hellmann, Monica B. Arniella, Mark Holton +38 more
2023Nature Genetics171 citations Open access
Semantic Scholar
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
Edward S. Kim, V. Velcheti, T. Mekhail, C. Yun +14 more
2022Nature Medicine167 citations Open access
Semantic Scholar
Precision therapy for RET-altered cancers with RET inhibitors
K. Thein, V. Velcheti, B. Mooers, Jie Wu +1 more
2021Trends in Cancer141 citations Open access
Semantic Scholar
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
G. Dy, R. Govindan, V. Velcheti, G. Falchook +20 more
2023Journal of Clinical Oncology123 citations Open access
Semantic Scholar
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, I. Datar +12 more
2022Journal for ImmunoTherapy of Cancer119 citations Open access
Semantic Scholar
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
Xinyuan Tong, Ayushi S. Patel, Eejung Kim, Hong-Jun Li +36 more
2024Cancer Cell99 citations Open access
Semantic Scholar
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
Yuanwang Pan, Han Han, Hai-Fang Hu, Hua Wang +29 more
2022Cancer Cell97 citations Open access
Semantic Scholar
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study
Maliazurina B. Saad, L. Hong, M. Aminu, N. Vokes +45 more
2023The Lancet Digital Health95 citations Open access
Semantic Scholar
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
J. Sabari, V. Velcheti, Kazuhide Shimizu, M. Strickland +15 more
2022Clinical Cancer Research90 citations Open access
Semantic Scholar
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Suman Mukhopadhyay, Hsinyi Huang, Ziyan Lin, Michela Ranieri +22 more
2023Cancer Research86 citations Open access
Semantic Scholar
Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors
Xiang-Xue Wang, Cristian Barrera, K. Bera, V. Viswanathan +11 more
2022Science Advances84 citations Open access
Semantic Scholar
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
S. Punekar, E. Shum, Cassandra Grello, S. Lau +1 more
2022Frontiers in Oncology76 citations Open access
Semantic Scholar
Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib
J. Bauml, Bob T. Li, V. Velcheti, R. Govindan +10 more
2021Lung Cancer67 citations Open access
Semantic Scholar
Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
V. Velcheti, Xiaohan Hu, B. Piperdi, T. Burke
2021Scientific Reports62 citations Open access
Semantic Scholar
Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas
Lawrence Hsu Lin, D. Allison, Yang Feng, G. Jour +9 more
2021Modern Pathology53 citations Open access
Semantic Scholar
P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100
S. Ramalingam, F. Skoulidis, R. Govindan, V. Velcheti +12 more
2021Journal of Thoracic Oncology53 citations Open access
Semantic Scholar
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome
Ruiwen Ding, P. Prasanna, Germán Corredor, Cristian Barrera +15 more
2022npj Precision Oncology50 citations Open access
Semantic Scholar
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Z. Piotrowska, D. S. Tan, E. Smit, A. Spira +11 more
2023Journal of Clinical Oncology48 citations Open access
Semantic Scholar
A tumor vasculature–based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors
M. Alilou, Mohammadhadi Khorrami, P. Prasanna, K. Bera +7 more
2022Science Advances37 citations Open access
Semantic Scholar
Spatial and single-cell profiling of human and murine lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception
Bo Zhu, Pingjun Chen, M. Aminu, Jianrong Li +48 more
2025Cancer Cell34 citations Open access
Semantic Scholar
Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.
U. Vaishampayan, P. Tomczak, J. Muzaffar, I. Winer +16 more
2022Journal of Clinical Oncology34 citations
Semantic Scholar
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer
Cristian Barrera, Germán Corredor, V. Viswanathan, Ruiwen Ding +17 more
2023npj Precision Oncology31 citations Open access
Semantic Scholar
Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
V. Velcheti, Xiaohan Hu, Ling-Feng Yang, M. Pietanza +1 more
2022Frontiers in Oncology31 citations Open access
Semantic Scholar
Distinguishing Granulomas from Adenocarcinomas by integrating stable and discriminating radiomic features on non-Contrast CT scans
Mohammadhadi Khorrami, K. Bera, R. Thawani, P. Rajiah +8 more
2021European Journal of Cancer31 citations Open access
Semantic Scholar
Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma
Igor Dolgalev, Hua Zhou, Nina Murrell, Hortense Le +36 more
2022bioRxiv30 citations Open access
Semantic Scholar
Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers
Nathaniel Braman, P. Prasanna, K. Bera, M. Alilou +13 more
2022Clinical Cancer Research30 citations Open access
Semantic Scholar
MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
B. Cho, R. Doebele, Jessica J. Lin, M. Nagasaka +12 more
202130 citations
Semantic Scholar
Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma
Pingjun Chen, Frank R. Rojas, Xin Hu, Alejandra G. Serrano +24 more
2023Modern Pathology28 citations Open access
Semantic Scholar
Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).
H. Yu, D. S. Tan, E. Smit, A. Spira +13 more
2022Journal of Clinical Oncology28 citations
Semantic Scholar
Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).
Z. Piotrowska, H. Yu, J. Yang, M. Koczywas +14 more
2021Journal of Clinical Oncology28 citations
Semantic Scholar
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Xinyuan Tong, Ayushi S. Patel, Eejung Kim, Hong-Jun Li +33 more
2023bioRxiv27 citations Open access
Semantic Scholar
Trends in Lung Cancer Incidence and Mortality (1990-2019) in the United States: A Comprehensive Analysis of Gender and State-Level Disparities
C. Jani, Harpreet Singh, Nour Abdallah, Christian Mouchati +5 more
2023JCO Global Oncology26 citations Open access
Semantic Scholar
Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
Stephen V. Liu, Xiaohan Hu, Ye Li, Bin Zhao +2 more
2022Frontiers in Oncology26 citations Open access
Semantic Scholar
Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
V. Velcheti, Xiaohan Hu, Ye Li, H. El-Osta +2 more
2022Cancers26 citations Open access
Semantic Scholar
Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.
Bob T. Li, V. Velcheti, T. Price, D. Hong +16 more
2022Journal of Clinical Oncology25 citations
Semantic Scholar
A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer
Xiang-Xue Wang, K. Bera, Cristian Barrera, Yu Zhou +9 more
2021EBioMedicine24 citations Open access
Semantic Scholar
Objective analysis and clinical significance of the spatial tumor infiltrating lymphocyte patterns in non-small cell lung cancer.
Miguel Lopez de Rodas, Yvonne Wang, Gang Peng, Jianlei Gu +7 more
2023Clinical Cancer Research19 citations Open access
Semantic Scholar
Extended Survival in Patients With Non–Small-Cell Lung Cancer–Associated Brain Metastases in the Modern Era
Assaf Berger, R. Mullen, K. Bernstein, J. Alzate +9 more
2023Neurosurgery18 citations
Semantic Scholar
Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.
Jessica J. Lin, A. Drilon, B. Cho, E. Felip +16 more
2023Journal of Clinical Oncology14 citations Open access
Semantic Scholar
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
Yuanwang Pan, Yuan Hao, Han Han, Ting Chen +19 more
2022Journal for ImmunoTherapy of Cancer14 citations Open access
Semantic Scholar
Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer.
Xin-Ke Zhang, R. DeClue, L. Herms, Mo Yang +5 more
2021Immunotherapy14 citations Open access
Semantic Scholar
Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors.
M. Johnson, D. Doroshow, T. Seiwert, M. Gibson +7 more
202114 citations
Semantic Scholar
Abstract CT008: Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100
G. Dy, R. Govindan, V. Velcheti, G. Falchook +18 more
2022Cancer Research12 citations
Semantic Scholar
TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11and/or KEAP1 and/or KRAS mutations.
F. Skoulidis, H. Borghaei, E. Garon, T. Leal +8 more
2024Journal of Clinical Oncology11 citations Open access
Semantic Scholar
P1.11-01 Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
H. Kim, C. Gridelli, D. Kapur, A. Tufman +16 more
2022Journal of Thoracic Oncology10 citations Open access
Semantic Scholar
Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)
B. Cho, J. Lin, D. Camidge, V. Velcheti +16 more
2022European Journal of Cancer10 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Madabhushi×8
Invite
A. Madabhushi — researcher profile on SciRah
F. Skoulidis×6
Invite
F. Skoulidis — researcher profile on SciRah
K. Schalper×6
Invite
K. Schalper — researcher profile on SciRah
P. Fu×6
Invite
P. Fu — researcher profile on SciRah

×5

Invite

Bob T. Li — researcher profile on SciRah

Invite

G. Dy — researcher profile on SciRah

Invite

R. Govindan — researcher profile on SciRah

Kwok Kei Sandra Wong×5

Invite

Kwok Kei Sandra Wong — researcher profile on SciRah

Cristian Barrera×5

Invite

Cristian Barrera — researcher profile on SciRah

Fiona Sherman×5

Invite

Fiona Sherman — researcher profile on SciRah

Invite

K. Bera — researcher profile on SciRah

Invite

G. Falchook — researcher profile on SciRah